<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03105336</url>
  </required_header>
  <id_info>
    <org_study_id>KTE-C19-105</org_study_id>
    <nct_id>NCT03105336</nct_id>
  </id_info>
  <brief_title>A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma</brief_title>
  <acronym>ZUMA-5</acronym>
  <official_title>A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite, A Gilead Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kite, A Gilead Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enroll approximately 50 adult subjects who have relapsed or refractory (r/r)
      iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease
      responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is
      made from the subjects own white blood cells which are genetically modified and grown to
      fight cancer. An objective response rate of 70% is targeted.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll approximately 50 adult subjects who have relapsed or refractory (r/r)
      iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease
      responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is
      made from the subjects own white blood cells which are genetically modified and grown to
      fight cancer. An objective response rate of 70% is targeted.

      All enrolled subjects will be screened for eligibility then will undergo leukapheresis to
      collect white blood cells for manufacturing. In preparation for the infusion with
      axicabtagene ciloleucel, subjects will undergo conditioning chemotherapy with
      cyclophosphamide and fludarabine for 3 days to help the study treatment be effective. After
      the product is manufactured and conditioning chemotherapy period is complete, subjects will
      be infused with axicabtagene ciloleucel and then monitored in a hospital for a minimum of 7
      days. Subjects will be followed by their study doctor for continued monitoring of the safety
      and effectiveness of the study treatment for approximately 3 months after receiving treatment
      and then will be followed for safety for up to an additional 3 Â½ years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>6 months</time_frame>
    <description>Complete response (CR) + partial response (PR) per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma (Cheson 2007) as determined by the study investigators.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>12 months</time_frame>
    <description>The time from the axicabtagene ciloleucel infusion date to the date of disease progression per the revised IWG Response Criteria for Malignant Lymphoma (Cheson 2007) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as the time from axicabtagene ciloleucel infusion to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of AEs</measure>
    <time_frame>12 months</time_frame>
    <description>The frequency of any AEs that occurred during study participation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical significant changes in lab values.</measure>
    <time_frame>12 months</time_frame>
    <description>The occurrence of any changes in lab values deemed to be clinically significant during study participation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Follicular Lymphoma</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Indolent Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>axicabtagene ciloleucel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>axicabtagene ciloleucel</intervention_name>
    <description>A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.</description>
    <arm_group_label>axicabtagene ciloleucel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Subject has [follicular lymphoma that has progressed within 24 months of first
             diagnosis and treatment with combination chemoimmunotherapy] (e.g. R-bendamustine,
             R-CHOP) OR Progression of iNHL within 6 months of completion of second or later line
             therapy containing both an anti-CD20 antibody and alkylating agent OR Progression of
             iNHL at any point following autologous transplantation.

             2) Subject has [measurable disease].

             3) Subject has no known presence or history of CNS involvement by lymphoma.

             4) If subject is on conventional systemic therapy or systemic inhibitory/stimulatory
             immune checkpoint therapy, subject is able to stop conventional therapy 2 weeks or 5
             half-lives, whichever is shorter, or immune checkpoint therapy 3 half-lives prior to
             planned leukapheresis.

             5) Subject has ECOG performance status of 0-1 and adequate renal, hepatic, pulmonary,
             and cardiac function

             6) Subject is not pregnant or breastfeeding (female subjects only) and is willing to
             use birth control from the time of consent through 6 months following CAR T cell
             infusion (both male and female subjects).B24

        Exclusion Criteria:

          -  1) Transformed FL

             2) Small lymphocytic lymphoma

             3) Histological Grade 3b FL

             4) Subject will have undergone autologous transplant within 6 weeks of planned
             leukapheresis or has undergone allogeneic transplant.

             5) Subject has evidence of involvement of the heart by lymphoma or requirement for
             urgent therapy due to ongoing or impending oncologic emergency (e.g. mass effect,
             tumor lysis syndrome, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wayne Godfrey, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Kite, A Gilead Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>844-454-KITE</phone>
    <email>medinfo@kitepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Winkle</last_name>
      <phone>480-256-3421</phone>
      <email>andrea.winkle@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Javier Munos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Kelly, MD</last_name>
      <email>kevin.kelly@med.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven de Vos, MD, PhD</last_name>
      <email>devos@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pashna Munshi, MD</last_name>
      <email>pashna.n.munshi@gunet.georgetown.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital and Clinics</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Luis</last_name>
      <phone>305-243-7648</phone>
      <email>nluis@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Scott</last_name>
      <email>matthew.scott@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystle Benedict</last_name>
      <phone>617-582-8713</phone>
      <email>Krystle_Benedict@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Caron Jacobson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center (URMC)</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frances Batarse</last_name>
      <phone>585-275-5825</phone>
      <email>frances_batarse@urmc.rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carla Casulo, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Szuminski</last_name>
      <phone>614-688-9796</phone>
      <email>nicole.szuminski@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Matthew</last_name>
      <phone>215-214-3125</phone>
      <email>richard.mathew@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Henry Fung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Fritz</last_name>
      <email>fritzm2@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Dorritie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Fukas</last_name>
      <email>fukaslj@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Allison Sehgal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Howell</last_name>
      <phone>615-341-7859</phone>
      <email>brittany.howell@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Ian Flinn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liliana Vallejo</last_name>
      <email>lnvallejo@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Sherry Adkins</last_name>
      <email>sadkins@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sattva Neelapu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Immunotherapy Trials Intake</last_name>
      <phone>206-606-4668</phone>
      <email>immunotherapy@seattlecca.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2017</study_first_submitted>
  <study_first_submitted_qc>April 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

